Hainan, China
Hainan, China
SEARCH FILTERS
Time filter
Source Type

HAIKOU, China, May 17, 2017 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE MKT: CPHI) ("China Pharma," the "Company" or "We"), an NYSE MKT listed corporation with its fully-integrated specialty pharmaceuticals subsidiary based in China, today announced its wholly-owned subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd., participated in PharmChina and API (Active Pharmaceutical Ingredient) China. The 77th PHARMCHINA, and the 78th API China takes place on May 15 - 18, 2017,  National Exhibition and Convention Center, Shanghai, China. With a long history and great influence in the APAC region, this event involves pharmaceutical research and development, production, sales and marketing; is one of the best platforms to understand the pulse and latest trends of this industry. There has been over 120,000 visitors mainly from pharmaceutical manufacturers, distributors/agents, and pharmacy chains. Hainan Helpson Medical & Biotechnology Co., Ltd., is showing around 20 products for the treatment of anti-infection & respiratory system diseases, central nervous system diseases, digestive diseases, and other diseases in this event; and is communicating with a wide range of existing and potential distributors and API suppliers. "To participate in this event is to further improve our market share, strengthen cooperation with upstream and downstream companies, in-depth understand frontier information, and explore global layout," China Pharma's President & CEO, Ms. Li Zhilin. "We have been actively talking to international API exhibitors to leverage any win-win cooperation models in the current pharmaceutical policy environment in China. We will continue enhancing our fundamentals in operating level to support and promote our long-term growth." China Pharma Holdings, Inc. is a specialty pharmaceutical company that develops, manufactures and markets a diversified portfolio of products focused on conditions with a high incidence and high mortality rates in China, including cardiovascular, CNS, infectious, and digestive diseases. The Company's cost-effective, high-margin business model is driven by market demand and supported by new GMP-certified product lines covering the major dosage forms. In addition, the Company has a broad and expanding nationwide distribution network across all major cities and provinces in China. The Company's wholly-owned subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd., is located in Haikou City, Hainan Province. For more information about China Pharma Holdings, Inc., please visit www.chinapharmaholdings.com. The Company routinely posts important information on its website. Certain statements in this press release constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Any statements set forth above that are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, which may include, but are not limited to, such factors as the achievability of financial guidance, success of new product development, unanticipated changes in product demand, increased competition, downturns in the Chinese economy, uncompetitive levels of research and development, and other information detailed from time to time in the Company's filings and future filings with the United States Securities and Exchange Commission. The forward-looking statements made herein speak only as of the date of this press release and the Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the Company's expectations except as required by applicable law or regulation. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/china-pharma-holdings-incs-wholly-owned-subsidiary-participated-in-pharmchinaapi-china-conferences-300459156.html


Hainan Helpson Medical & Biotechnology Co., Ltd., is showing around 20 products for the treatment of anti-infection & respiratory system diseases, central nervous system diseases, digestive diseases, and other diseases in this event; and is communicating with a wide range of existing and potential distributors and API suppliers. "To participate in this event is to further improve our market share, strengthen cooperation with upstream and downstream companies, in-depth understand frontier information, and explore global layout," China Pharma's President & CEO, Ms. Li Zhilin. "We have been actively talking to international API exhibitors to leverage any win-win cooperation models in the current pharmaceutical policy environment in China. We will continue enhancing our fundamentals in operating level to support and promote our long-term growth." China Pharma Holdings, Inc. is a specialty pharmaceutical company that develops, manufactures and markets a diversified portfolio of products focused on conditions with a high incidence and high mortality rates in China, including cardiovascular, CNS, infectious, and digestive diseases. The Company's cost-effective, high-margin business model is driven by market demand and supported by new GMP-certified product lines covering the major dosage forms. In addition, the Company has a broad and expanding nationwide distribution network across all major cities and provinces in China. The Company's wholly-owned subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd., is located in Haikou City, Hainan Province. For more information about China Pharma Holdings, Inc., please visit www.chinapharmaholdings.com. The Company routinely posts important information on its website. Certain statements in this press release constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Any statements set forth above that are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, which may include, but are not limited to, such factors as the achievability of financial guidance, success of new product development, unanticipated changes in product demand, increased competition, downturns in the Chinese economy, uncompetitive levels of research and development, and other information detailed from time to time in the Company's filings and future filings with the United States Securities and Exchange Commission. The forward-looking statements made herein speak only as of the date of this press release and the Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the Company's expectations except as required by applicable law or regulation. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/china-pharma-holdings-incs-wholly-owned-subsidiary-participated-in-pharmchinaapi-china-conferences-300459156.html


HAIKOU CITY, China, May 8, 2017 /PRNewswire/ -- China Pharma Holdings, Inc. ("China Pharma") (NYSE MKT: CPHI), an NYSE MKT listed corporation with its fully-integrated specialty pharmaceuticals subsidiary based in China, today announced that it plans to hold its first quarter 2017 earnings conference call on Friday, May 12, 2017 at 8:30 a.m. ET. Listeners may access the call by dialing 1-866-519-4004 or 65-671-350-90 for international callers, Conference ID # 20452439.  A replay of the call will be accessible through May 20, 2017 by dialing 1-855-452-5696 or 61-281-990-299 for international callers, Conference ID # 20452439.


HAIKOU CITY, China, May 8, 2017 /PRNewswire/ -- China Pharma Holdings, Inc. ("China Pharma") (NYSE MKT: CPHI), an NYSE MKT listed corporation with its fully-integrated specialty pharmaceuticals subsidiary based in China, today announced that it plans to hold its first quarter 2017 earnings conference call on Friday, May 12, 2017 at 8:30 a.m. ET. Listeners may access the call by dialing 1-866-519-4004 or 65-671-350-90 for international callers, Conference ID # 20452439.  A replay of the call will be accessible through May 20, 2017 by dialing 1-855-452-5696 or 61-281-990-299 for international callers, Conference ID # 20452439. China Pharma Holdings, Inc. is a specialty pharmaceutical company that develops, manufactures and markets a diversified portfolio of products focused on conditions with a high incidence and high mortality rates in China, including cardiovascular, CNS, infectious, and digestive diseases. The Company's cost-effective business model is driven by market demand and supported by new GMP-certified product lines covering the major dosage forms. In addition, the Company has a broad and expanding nationwide distribution network across all major cities and provinces in China. The Company's wholly-owned subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd., is located in Haikou City, Hainan Province. For more information about China Pharma Holdings, Inc., please visit http://www.chinapharmaholdings.com. The Company routinely posts important information on its website. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/cphi-to-hold-first-quarter-2017-earnings-conference-call-on-friday-may-12-2017-at-830-am-et-300452902.html


Listeners may access the call by dialing 1-866-519-4004 or 65-671-350-90 for international callers, Conference ID # 66755768.  A replay of the call will be accessible through August 23, 2017 by dialing 1-855-452-5696 or 61-281-990-299 for international callers, Conference ID # 66755768. China Pharma Holdings, Inc. is a specialty pharmaceutical company that develops, manufactures and markets a diversified portfolio of products focused on conditions with a high incidence and high mortality rates in China, including cardiovascular, CNS, infectious, and digestive diseases. The Company's cost-effective business model is driven by market demand and supported by new GMP-certified product lines covering the major dosage forms. In addition, the Company has a broad and expanding nationwide distribution network across all major cities and provinces in China. The Company's wholly-owned subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd., is located in Haikou City, Hainan Province. For more information about China Pharma Holdings, Inc., please visit http://www.chinapharmaholdings.com. The Company routinely posts important information on its website.


News Article | August 15, 2017
Site: www.prnewswire.com

"We experienced a slight revenue decrease in the second quarter of 2017 compared to the same period last year, which was primarily due to the current status of Chinese health care reform. Recent reforms require health care institutions to strictly control 'the proportion of drug sales to total revenue', in an effort to prevent hospitals from subsidizing medical services with inflated prescription drug prices. This background led to a significant decrease of drug purchases from health care institutions and impacted our drug sales in this period," said Ms. Zhilin Li, China Pharma's Chairman and CEO. Ms. Li continued, "Nevertheless, increasing sales remains our top priority. Management will continue to vigorously promote sales by actively participating in the recent provincial market openings to receive new drug tender offers and by further exploring the basic medical market. The ongoing generic drug consistency evaluations and reform of China's drug production registration and review policies will have a major impact on the future development of our industry and may change its business patterns. We will continue to actively adapt to state policy guidance and further evaluate market conditions for our current existing products, pipeline products, and competition in the market in order to optimize our development strategy." Revenue decreased by 17.7% to $2.9 million for the three months ended June 30, 2017, as compared to $3.5 million for the three months ended June 30, 2016. This decrease was mainly due to the impact from the ongoing Chinese health care reform. Gross profit for the three months ended June 30, 2017 was $0.6 million, compared to $0.5 million in the same period last year. Our gross profit margin in the three months ended June 30, 2017 was 22.2% compared to 13.6% in the same period last year. This increase was primarily due to more sales of higher margin products in this period compared to the sales performance in the same period last year. Our selling expenses for the three months ended June 30, 2017 were $0.8 million, a decrease of $0.1 million, compared to $0.9 million for the three months ended June 30, 2016. Selling expenses accounted for 27.5% of the total revenue in the three months ended June 30, 2017 compared to 24.2% in the same period last year. Because of adjustments in our sales practices resulting from health-care reform policies, despite the overall decrease in sales, we may require additional personnel and expenses to support our sales and the collection of accounts receivable. Our general and administrative expenses for the three months ended June 30, 2017 were $0.6 million, which represented a decrease of $0.2 million compared to $0.8 million in the same period last year. General and administrative expenses accounted for 21% and 22% of our total revenues in three months ended June 30, 2017 and 2016, respectively. Our bad debt expenses for the three months ended June 30, 2017 was $0.4 million, compared to $0.5 million in the same period last year. During the three months ended June 30, 2017 and 2016 the Company recognized an impairment related to "Advances for purchases of intangible assets" in the amount of $1.0 million and $0.8 million, respectively. The Company reviewed the contracts relating to advances made for purchases of intangible assets with independent laboratories and determined that the Company's advances to independent laboratories for several formulas were impaired. Net loss for the three months ended June 30, 2017 was $2.3 million, compared to net loss of $2.5 million for the three months ended June 30, 2016. For the six months ended June 30, 2017, our sales revenue was $6.2 million, which represented a decrease of $1.0 million, or 13.7%, from the $7.2 million in the corresponding period of 2016. Gross profit for the six months ended June 30, 2017 was $1.4 million, compared to $1.1 million in the same period of 2016. Gross profit margin for the six months ended June 30, 2017 and 2016 were 22.0% and 15.6%, respectively.  The increase in gross profit margin was mainly due to more higher-margin products sold in this period. Our operating loss for the six months ended June 30, 2017 was approximately $2.9 million, compared to $3.5 million for the same period of 2016, which represented an improvement of $0.6 million. This was mainly due to the increase in gross profit margin and decrease in bad debt expense in the first half of 2017 compared to the same period last year. Net loss was $3.3 million, or $0.07 per basic and diluted share for the six months ended June 30, 2017, compared to $4.0 million, or $0.09 per basic and diluted share, for the same period a year ago. As of June 30, 2017, the Company had cash and cash equivalents of $1.7 million compared to $2.7 million as of December 31, 2016. Working capital decreased to $6.7 million as of June 30, 2017 from $7.1 million as of December 31, 2016; and the current ratio was 1.6 and 1.7 times at June 30, 2017 and December 31, 2016, respectively. Our net accounts receivable balance decreased to $3.2 million as of June 30, 2017 from $4.0 million as of December 31, 2016. The Company will hold a conference call at 8:30 am E.T. on August 15, 2017 to discuss the results of second quarter 2017. Listeners may access the call by dialing 1-866-519-4004 or 65-671-350-90 for international callers, Conference ID # 66755768.  A replay of the call will be accessible through August 23, 2017 by dialing 1-855-452-5696 or 61-281-990-299 for international callers, Conference ID # 66755768. China Pharma Holdings, Inc. is a specialty pharmaceutical company that develops, manufactures and markets a diversified portfolio of products focused on conditions with a high incidence and high mortality rates in China, including cardiovascular, CNS, infectious, and digestive diseases. The Company's cost-effective, high-margin business model is driven by market demand and supported by new GMP-certified product lines covering the major dosage forms. In addition, the Company has a broad and expanding nationwide distribution network across all major cities and provinces in China. The Company's wholly-owned subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd., is located in Haikou City, Hainan Province. For more information about China Pharma Holdings, Inc., please visit www.chinapharmaholdings.com. The Company routinely posts important information on its website. Certain statements in this press release constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Any statements set forth above that are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, which may include, but are not limited to, such factors as the achievability of financial guidance, success of new product development, unanticipated changes in product demand, increased competition, downturns in the Chinese economy, uncompetitive levels of research and development, and other information detailed from time to time in the Company's filings and future filings with the United States Securities and Exchange Commission. The forward-looking statements made herein speak only as of the date of this press release and the Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the Company's expectations except as required by applicable law or regulation.


News Article | August 15, 2017
Site: en.prnasia.com

HAIKOU CITY, China, Aug. 15, 2017 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE MKT: CPHI) ("China Pharma," the "Company" or "We"), an NYSE American listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China, today announced financial results for the quarter ended June 30, 2017. "We experienced a slight revenue decrease in the second quarter of 2017 compared to the same period last year, which was primarily due to the current status of Chinese health care reform. Recent reforms require health care institutions to strictly control 'the proportion of drug sales to total revenue', in an effort to prevent hospitals from subsidizing medical services with inflated prescription drug prices. This background led to a significant decrease of drug purchases from health care institutions and impacted our drug sales in this period," said Ms. Zhilin Li, China Pharma's Chairman and CEO. Ms. Li continued, "Nevertheless, increasing sales remains our top priority. Management will continue to vigorously promote sales by actively participating in the recent provincial market openings to receive new drug tender offers and by further exploring the basic medical market. The ongoing generic drug consistency evaluations and reform of China's drug production registration and review policies will have a major impact on the future development of our industry and may change its business patterns. We will continue to actively adapt to state policy guidance and further evaluate market conditions for our current existing products, pipeline products, and competition in the market in order to optimize our development strategy." Revenue decreased by 17.7% to $2.9 million for the three months ended June 30, 2017, as compared to $3.5 million for the three months ended June 30, 2016. This decrease was mainly due to the impact from the ongoing Chinese health care reform. Gross profit for the three months ended June 30, 2017 was $0.6 million, compared to $0.5 million in the same period last year. Our gross profit margin in the three months ended June 30, 2017 was 22.2% compared to 13.6% in the same period last year. This increase was primarily due to more sales of higher margin products in this period compared to the sales performance in the same period last year. Our selling expenses for the three months ended June 30, 2017 were $0.8 million, a decrease of $0.1 million, compared to $0.9 million for the three months ended June 30, 2016. Selling expenses accounted for 27.5% of the total revenue in the three months ended June 30, 2017 compared to 24.2% in the same period last year. Because of adjustments in our sales practices resulting from health-care reform policies, despite the overall decrease in sales, we may require additional personnel and expenses to support our sales and the collection of accounts receivable. Our general and administrative expenses for the three months ended June 30, 2017 were $0.6 million, which represented a decrease of $0.2 million compared to $0.8 million in the same period last year. General and administrative expenses accounted for 21% and 22% of our total revenues in three months ended June 30, 2017 and 2016, respectively. Our bad debt expenses for the three months ended June 30, 2017 was $0.4 million, compared to $0.5 million in the same period last year. During the three months ended June 30, 2017 and 2016 the Company recognized an impairment related to "Advances for purchases of intangible assets" in the amount of $1.0 million and $0.8 million, respectively. The Company reviewed the contracts relating to advances made for purchases of intangible assets with independent laboratories and determined that the Company's advances to independent laboratories for several formulas were impaired. Net loss for the three months ended June 30, 2017 was $2.3 million, compared to net loss of $2.5 million for the three months ended June 30, 2016. For the six months ended June 30, 2017, our sales revenue was $6.2 million, which represented a decrease of $1.0 million, or 13.7%, from the $7.2 million in the corresponding period of 2016. Gross profit for the six months ended June 30, 2017 was $1.4 million, compared to $1.1 million in the same period of 2016. Gross profit margin for the six months ended June 30, 2017 and 2016 were 22.0% and 15.6%, respectively.  The increase in gross profit margin was mainly due to more higher-margin products sold in this period. Our operating loss for the six months ended June 30, 2017 was approximately $2.9 million, compared to $3.5 million for the same period of 2016, which represented an improvement of $0.6 million. This was mainly due to the increase in gross profit margin and decrease in bad debt expense in the first half of 2017 compared to the same period last year. Net loss was $3.3 million, or $0.07 per basic and diluted share for the six months ended June 30, 2017, compared to $4.0 million, or $0.09 per basic and diluted share, for the same period a year ago. As of June 30, 2017, the Company had cash and cash equivalents of $1.7 million compared to $2.7 million as of December 31, 2016. Working capital decreased to $6.7 million as of June 30, 2017 from $7.1 million as of December 31, 2016; and the current ratio was 1.6 and 1.7 times at June 30, 2017 and December 31, 2016, respectively. Our net accounts receivable balance decreased to $3.2 million as of June 30, 2017 from $4.0 million as of December 31, 2016. The Company will hold a conference call at 8:30 am E.T. on August 15, 2017 to discuss the results of second quarter 2017. Listeners may access the call by dialing 1-866-519-4004 or 65-671-350-90 for international callers, Conference ID # 66755768.  A replay of the call will be accessible through August 23, 2017 by dialing 1-855-452-5696 or 61-281-990-299 for international callers, Conference ID # 66755768. China Pharma Holdings, Inc. is a specialty pharmaceutical company that develops, manufactures and markets a diversified portfolio of products focused on conditions with a high incidence and high mortality rates in China, including cardiovascular, CNS, infectious, and digestive diseases. The Company's cost-effective, high-margin business model is driven by market demand and supported by new GMP-certified product lines covering the major dosage forms. In addition, the Company has a broad and expanding nationwide distribution network across all major cities and provinces in China. The Company's wholly-owned subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd., is located in Haikou City, Hainan Province. For more information about China Pharma Holdings, Inc., please visit www.chinapharmaholdings.com. The Company routinely posts important information on its website. Certain statements in this press release constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Any statements set forth above that are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, which may include, but are not limited to, such factors as the achievability of financial guidance, success of new product development, unanticipated changes in product demand, increased competition, downturns in the Chinese economy, uncompetitive levels of research and development, and other information detailed from time to time in the Company's filings and future filings with the United States Securities and Exchange Commission. The forward-looking statements made herein speak only as of the date of this press release and the Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the Company's expectations except as required by applicable law or regulation.


News Article | May 12, 2017
Site: en.prnasia.com

HAIKOU CITY, China, May 12, 2017 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE MKT: CPHI) ("China Pharma,"  the "Company" or "We"), an NYSE MKT listed corporation with its fully-integrated specialty pharmaceuticals subsidiary based in China, today announced financial results for the quarter ended March 31, 2017. "We experienced a slight revenue decrease in the first quarter of 2017 compared to the same period last year, which was mainly due to a more significant impact from an earlier Spring Festival holiday in 2017. However, we believed that our overall financial performance has improved, taking into consideration the increased gross profit margin and decreased net loss," said Ms. Zhilin Li, China Pharma's Chairman and CEO.  Ms. Li continued, "Nevertheless, increasing sales remains our top priority. Management will continue to vigorously promote sales by actively participating in the recent opening of the new provincial drug tender offer and further exploring basic medical market. We continue to believe that demand for pharmaceutical products is huge and steady in China. The ongoing generic drug consistency evaluations and reform of China's drug production registration and review policies will have a major impact on the future development of our industry and may change its business patterns. We will continue to actively adapt to state policy guidance and further evaluate market conditions for our current existing products, pipeline products, and competition in the market in order to optimize our development strategy." Revenue decreased by 9.8% to $3.3 million for the three months ended March 31, 2017, as compared to $3.6 million for the three months ended March 31, 2016. This decrease was primarily due to the impact from Chinese Spring Festival on purchase and logistic activities. Gross profit for the three months ended March 31, 2017 was $0.7 million, compared to $0.6 million in the same period last year. Our gross profit margin in the three months ended March 31, 2017 was 21.9% compared to 17.6% in the same period last year. This increase was primarily due to the increase in gross profit margins of our major products in this period. Our selling expenses for the three months ended March 31, 2017 were $0.7 million, a decrease of $0.3 million, compared to $1.0 million for the three months ended March 31, 2016. Selling expenses accounted for 21.8% of the total revenue in the three months ended March 31, 2017 compared to 26.6% in the same period last year.  Because of adjustments in our sales practices resulting from health-care reform policies, despite the overall decrease in sales, we may require additional personnel and expenses to support our sales and the collection of accounts receivable. Our general and administrative expenses for the three months ended March 31, 2017 were $0.4 million, which represented an increase of $0.1 million compared to $0.3 million in the same period last year. General and administrative expenses accounted for 12.7% and 8.7% of our total revenues in three months ended March 31, 2017 and 2016, respectively. This increase was primarily due to several major payments for listing maintenance happened in the three months ended March 31, 2017. Our bad debt expenses for the three months ended March 31, 2017 was $0.4 million, which represented a decrease of $0.2 million compared to $0.6 million in the same period last year. The decline in our bad debt expenses was mainly the result of the decline in our revenues in recent years, which also led to the corresponding decline in the net amount of accounts receivable aging over one year (according to our current accounting policy, we are required to recognize a 70% bad debt allowance). Our income tax expense was $0.03 million and $0.02 million for the three months ended March 31, 2017 and 2016, respectively. The expense arose as a result of certain deferred tax liabilities recognized in prior years. We renewed our "National High-Tech Enterprise" status with the Chinese government in the third quarter of 2013. With this designation, for the years ending December 31, 2015 and 2016, we enjoy a preferential tax rate of 15%, which is notably lower than the statutory income tax rate of 25%. However, our recent net loss results have put the Company in an unfavorable position for the potential renewal of "National High-Tech Enterprise" status in 2017, and after evaluating the feasibility of such a renewal, the Company has decided not to renew this status. As a result, our tax rate for 2017 and the foreseeable future will be 25%. Net loss for the first quarter 2017 was $1.0 million, or $(0.02) per basic and diluted share, compared to net loss of $1.6 million, or $(0.04) per basic and diluted share for the same period of 2016. The decrease in net loss was mainly a result of the increase in gross profit margin and decrease in bad debt expenses. As of March 31, 2017, the Company had cash and cash equivalents of $2.5 million compared to $2.7 million as of December 31, 2016. Working capital decreased to $6.9 million as of March 31, 2017 from $7.1 million as of December 31, 2016; and the current ratio was 1.7 times in both March 31, 2017 and December 31, 2016, respectively. Our accounts receivable balance decreased to $3.7 million as of March 31, 2017 from $4.0 million as of December 31, 2016. The Company will hold a conference call at 8:30 am E.T. on May 12, 2017 to discuss the results of first quarter 2017. Listeners may access the call by dialing 1-866-519-4004 or 65-671-350-90 for international callers, Conference ID # 20452439.  A replay of the call will be accessible through May 20, 2017 by dialing 1-855-452-5696 or 61-281-990-299 for international callers, Conference ID # 20452439. China Pharma Holdings, Inc. is a specialty pharmaceutical company that develops, manufactures and markets a diversified portfolio of products focused on conditions with a high incidence and high mortality rates in China, including cardiovascular, CNS, infectious, and digestive diseases. The Company's cost-effective, high-margin business model is driven by market demand and supported by new GMP-certified product lines covering the major dosage forms. In addition, the Company has a broad and expanding nationwide distribution network across all major cities and provinces in China. The Company's wholly-owned subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd., is located in Haikou City, Hainan Province. For more information about China Pharma Holdings, Inc., please visit www.chinapharmaholdings.com. The Company routinely posts important information on its website. Certain statements in this press release constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Any statements set forth above that are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, which may include, but are not limited to, such factors as the achievability of financial guidance, success of new product development, unanticipated changes in product demand, increased competition, downturns in the Chinese economy, uncompetitive levels of research and development, and other information detailed from time to time in the Company's filings and future filings with the United States Securities and Exchange Commission. The forward-looking statements made herein speak only as of the date of this press release and the Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the Company's expectations except as required by applicable law or regulation. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/china-pharma-holdings-inc-reports-first-quarter-2017-financial-results-300456655.html


News Article | May 12, 2017
Site: www.prnewswire.com

"We experienced a slight revenue decrease in the first quarter of 2017 compared to the same period last year, which was mainly due to a more significant impact from an earlier Spring Festival holiday in 2017. However, we believed that our overall financial performance has improved, taking into consideration the increased gross profit margin and decreased net loss," said Ms. Zhilin Li, China Pharma's Chairman and CEO.  Ms. Li continued, "Nevertheless, increasing sales remains our top priority. Management will continue to vigorously promote sales by actively participating in the recent opening of the new provincial drug tender offer and further exploring basic medical market. We continue to believe that demand for pharmaceutical products is huge and steady in China. The ongoing generic drug consistency evaluations and reform of China's drug production registration and review policies will have a major impact on the future development of our industry and may change its business patterns. We will continue to actively adapt to state policy guidance and further evaluate market conditions for our current existing products, pipeline products, and competition in the market in order to optimize our development strategy." Revenue decreased by 9.8% to $3.3 million for the three months ended March 31, 2017, as compared to $3.6 million for the three months ended March 31, 2016. This decrease was primarily due to the impact from Chinese Spring Festival on purchase and logistic activities. Gross profit for the three months ended March 31, 2017 was $0.7 million, compared to $0.6 million in the same period last year. Our gross profit margin in the three months ended March 31, 2017 was 21.9% compared to 17.6% in the same period last year. This increase was primarily due to the increase in gross profit margins of our major products in this period. Our selling expenses for the three months ended March 31, 2017 were $0.7 million, a decrease of $0.3 million, compared to $1.0 million for the three months ended March 31, 2016. Selling expenses accounted for 21.8% of the total revenue in the three months ended March 31, 2017 compared to 26.6% in the same period last year.  Because of adjustments in our sales practices resulting from health-care reform policies, despite the overall decrease in sales, we may require additional personnel and expenses to support our sales and the collection of accounts receivable. Our general and administrative expenses for the three months ended March 31, 2017 were $0.4 million, which represented an increase of $0.1 million compared to $0.3 million in the same period last year. General and administrative expenses accounted for 12.7% and 8.7% of our total revenues in three months ended March 31, 2017 and 2016, respectively. This increase was primarily due to several major payments for listing maintenance happened in the three months ended March 31, 2017. Our bad debt expenses for the three months ended March 31, 2017 was $0.4 million, which represented a decrease of $0.2 million compared to $0.6 million in the same period last year. The decline in our bad debt expenses was mainly the result of the decline in our revenues in recent years, which also led to the corresponding decline in the net amount of accounts receivable aging over one year (according to our current accounting policy, we are required to recognize a 70% bad debt allowance). Our income tax expense was $0.03 million and $0.02 million for the three months ended March 31, 2017 and 2016, respectively. The expense arose as a result of certain deferred tax liabilities recognized in prior years. We renewed our "National High-Tech Enterprise" status with the Chinese government in the third quarter of 2013. With this designation, for the years ending December 31, 2015 and 2016, we enjoy a preferential tax rate of 15%, which is notably lower than the statutory income tax rate of 25%. However, our recent net loss results have put the Company in an unfavorable position for the potential renewal of "National High-Tech Enterprise" status in 2017, and after evaluating the feasibility of such a renewal, the Company has decided not to renew this status. As a result, our tax rate for 2017 and the foreseeable future will be 25%. Net loss for the first quarter 2017 was $1.0 million, or $(0.02) per basic and diluted share, compared to net loss of $1.6 million, or $(0.04) per basic and diluted share for the same period of 2016. The decrease in net loss was mainly a result of the increase in gross profit margin and decrease in bad debt expenses. As of March 31, 2017, the Company had cash and cash equivalents of $2.5 million compared to $2.7 million as of December 31, 2016. Working capital decreased to $6.9 million as of March 31, 2017 from $7.1 million as of December 31, 2016; and the current ratio was 1.7 times in both March 31, 2017 and December 31, 2016, respectively. Our accounts receivable balance decreased to $3.7 million as of March 31, 2017 from $4.0 million as of December 31, 2016. The Company will hold a conference call at 8:30 am E.T. on May 12, 2017 to discuss the results of first quarter 2017. Listeners may access the call by dialing 1-866-519-4004 or 65-671-350-90 for international callers, Conference ID # 20452439.  A replay of the call will be accessible through May 20, 2017 by dialing 1-855-452-5696 or 61-281-990-299 for international callers, Conference ID # 20452439. China Pharma Holdings, Inc. is a specialty pharmaceutical company that develops, manufactures and markets a diversified portfolio of products focused on conditions with a high incidence and high mortality rates in China, including cardiovascular, CNS, infectious, and digestive diseases. The Company's cost-effective, high-margin business model is driven by market demand and supported by new GMP-certified product lines covering the major dosage forms. In addition, the Company has a broad and expanding nationwide distribution network across all major cities and provinces in China. The Company's wholly-owned subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd., is located in Haikou City, Hainan Province. For more information about China Pharma Holdings, Inc., please visit www.chinapharmaholdings.com. The Company routinely posts important information on its website. Certain statements in this press release constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Any statements set forth above that are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, which may include, but are not limited to, such factors as the achievability of financial guidance, success of new product development, unanticipated changes in product demand, increased competition, downturns in the Chinese economy, uncompetitive levels of research and development, and other information detailed from time to time in the Company's filings and future filings with the United States Securities and Exchange Commission. The forward-looking statements made herein speak only as of the date of this press release and the Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the Company's expectations except as required by applicable law or regulation. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/china-pharma-holdings-inc-reports-first-quarter-2017-financial-results-300456655.html


News Article | September 12, 2017
Site: www.prnewswire.com

The Company's common stock will continue to be listed on the NYSE American while it attempts to regain compliance with the Listing Standards, subject to the Company's compliance with other continued listing requirements. The NYSE American notification does not affect the Company's business operations or its reporting obligations under the Securities and Exchange Commission regulations and rules and does not conflict with or cause an event of default under any of the Company's material agreements. Based in Haikou, Hainan Province, China, China Pharma Holdings, Inc. is a publicly traded company engaged in the development, manufacture and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions. The Company offers its products through distributors, as well as through its network of 16 sales offices and approximately 1,000 sales representatives. For more information, view the Company's website at http://www.chinapharmaholdings.com. The Company routinely posts important information on its website. The information in this release includes certain forward-looking statements that are based on assumptions that in the future may prove not to have been accurate, including the Company's ability to submit and execute on a plan to regain compliance with NYSE American listing standards. The ability to execute a plan is subject to a number of risks described in the company's documents and reports filed from time to time with the Securities and Exchange Commission, which reports are available from the Company and the United States Securities and Exchange Commission ("SEC"). Other than required by applicable SEC regulations and rules, the Company undertakes no obligation to update its forward-looking statements.

Loading China Pharma collaborators
Loading China Pharma collaborators